TRIL

Q: What is the price of Trillium Therapeutics (TRIL) today?

The price of Trillium Therapeutics (TRIL) today is $ 0.00, with return of 0% compared to the last year. The price of Trillium Therapeutics (TRIL) started the year trading around $ 20.13 and today it is at $ 0.00. Follow the real-time price chart, the historical price of Trillium Therapeutics (TRIL) and international markets.

Q: When does Trillium Therapeutics (TRIL) pay dividends?

Trillium Therapeutics (TRIL) did not distribute dividends in the last year.

Q: Is Trillium Therapeutics (TRIL) worth it?

Currently, Trillium Therapeutics (TRIL) is priced at $ 0.00, with a P/E of 31.67%, representing a deviation of 0% from its historical average P/E. In the last year, the stock showed a variation of 0 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 0.00%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Trillium Therapeutics (TRIL) stock?

Investing in stocks of Trillium Therapeutics (TRIL) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Trillium Therapeutics (TRIL) yield today?

The yield of Trillium Therapeutics (TRIL) was 0.00% in the last month, 0.00% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Trillium Therapeutics (TRIL) today, the total investment would be $ 0.00, based on the current price of $ 0.00.If past performance were to repeat, the return on your investment would be:In 1 year: $ 0.00In 5 years: $ 0.00In 10 years: $ 0.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Trillium Therapeutics Inc.

Price

$ -

return (12m)

0.00%

p/e

31.67

p/bv

0.00

DIVIDEND YIELD

0.00%

TRIL price

TRIL

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment TRIL

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals TRIL

review the fundamentals of Trillium Therapeutics shares

P/E

31.67

Sector: -3.75 Industry: -3.75

P/S (PSR)

23,970.07

Sector: -4.18 Industry: -4.18

P/BV

0.00

Sector: 1.79 Industry: 1.79

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

0.00%

Sector: -62.10% Industry: -62.10%

ROE

0.00%

Sector: -62.98% Industry: -62.98%

ROIC

Sector: -1,220.49% Industry: -1,220.49%

NET MARGIN

100.00%

Sector: -39.10% Industry: -39.10%

GROSS MARGIN

76.74%

Sector: 38.12% Industry: 38.12%

OPERATING MARGIN

-100.00%

Sector: -39.31% Industry: -39.31%

EV/EBITDA

31.88

Sector: -3.57 Industry: -3.57

EV/EBIT

31.95

Sector: -3.78 Industry: -3.78

PRICE-TO-ASSETS

Sector: 1.30 Industry: 1.30

BVPS

Sector: 1.88 Industry: 1.88

EPS

0.63

Sector: -2.04 Industry: -2.04

EQUITY-TO-ASSETS RATIO

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

Sector: 0.39 Industry: 0.39

CAGR REVENUE 5 YEARS

10.17%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

Fundamentals TRIL

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.61	7.31	33.81%	2.16%	$ 579.24 B	28.46%
PFE	19.79	1.65	8.35%	6.36%	$ 153.75 B	12.42%
ABBV	87.56	0.00	0.00%	3.18%	$ 370.01 B	6.91%
NVO	10.22	5.26	51.50%	4.68%	$ 160.05 B	33.05%
MRK	16.27	0.00	0.00%	2.74%	$ 296.92 B	28.08%
AZN	28.58	6.00	20.99%	1.70%	$ 292.24 B	17.41%
GILD	19.48	7.33	37.62%	2.39%	$ 165.80 B	28.90%
BMY	16.90	-3.50	-20.72%	4.25%	$ 119.19 B	14.64%
ZTS	18.57	14.90	80.25%	1.79%	$ 49.65 B	28.23%
REGN	16.87	2.43	14.41%	0.49%	$ 75.98 B	31.41%
HALO	22.95	148.99	649.21%	0.00%	$ 7.27 B	22.69%
AMGN	24.38	21.71	89.06%	2.77%	$ 187.99 B	20.98%
MCK	24.38	-1,068.68	-4,383.84%	0.36%	$ 105.80 B	1.09%
VRTX	27.83	5.89	21.18%	0.00%	$ 110.00 B	32.94%
CAH	29.33	-18.06	-61.56%	0.99%	$ 48.75 B	0.68%
ADMA	14.98	4.61	30.78%	0.00%	$ 2.20 B	28.80%
BIIB	20.90	1.48	7.08%	0.00%	$ 27.02 B	13.07%
HRMY	9.53	1.74	18.24%	0.00%	$ 1.51 B	18.27%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

TRIL Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Trillium Therapeutics

Trillium Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

22 years

Founded: 2004

2009

Time since IPO - 17 years

33

Employees

The Company Trillium Therapeutics Inc. (United States), is listed on Nasdaq with a market value of $ 2.06 Billions, having an equity of $ -.

With a total of 33 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 86.00 Thousand, which generated a loss in the amount of $ 65.08 Millions.

As for its main indicators, the Company has a P/E ratio of 31.67, a P/BV ratio of 0.00 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker TRIL.

Market cap

$ 2.06 Billions

Net worth

$ -

US$ -

Assets

$ -

US$ -

Total Shares Outstanding

103.78 Millions

103,782,000

Average Daily Trading Volume

$ 1.51 Thousand

US$ 1,505.90

Sector

Health Care

Industry

Biotechnology

TRIL

TRIL revenue and profits

Financial Results TRIL

DRAG THE FRAME TO SEE MORE DATA

TRIL cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 884.28 23,83% (12M)

P/E

24.38

0.36%

ROE

-4,383.84%

P/BV

-1,068.68

CAH - Cardinal Health

$ 214.05 58,49% (12M)

P/E

29.33

0.99%

ROE

-61.56%

P/BV

-18.06

JNJ - Johnson & Johnson

$ 243.04 56,31% (12M)

P/E

21.61

2.16%

ROE

33.81%

P/BV

7.31

PFE - Pfizer

$ 28.32 25,05% (12M)

P/E

19.79

6.36%

ROE

8.35%

P/BV

1.65

ABBV - AbbVie

$ 208.84 7,85% (12M)

P/E

87.56

3.18%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 120.87 46,25% (12M)

P/E

16.27

2.74%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 203.49 51,28% (12M)

P/E

28.58

1.70%

ROE

20.99%

P/BV

6.00

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 884.28 23,83% (12 M)

P/L

24.38

0.36%

ROE

-4,383.84%

P/VP

-1,068.68

CAH - Cardinal Health

$ 214.05 58,49% (12 M)

P/L

29.33

0.99%

ROE

-61.56%

P/VP

-18.06

JNJ - Johnson & Johnson

$ 243.04 56,31% (12 M)

P/L

21.61

2.16%

ROE

33.81%

P/VP

7.31

PFE - Pfizer

$ 28.32 25,05% (12 M)

P/L

19.79

6.36%

ROE

8.35%

P/VP

1.65

ABBV - AbbVie

$ 208.84 7,85% (12 M)

P/L

87.56

3.18%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 120.87 46,25% (12 M)

P/L

16.27

2.74%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 203.49 51,28% (12 M)

P/L

28.58

1.70%

ROE

20.99%

P/VP

6.00

Frequently Asked Questions

What is the price of Trillium Therapeutics (TRIL) today?

The price of Trillium Therapeutics (TRIL) today is $ 0.00, with return of 0% compared to the last year. The price of Trillium Therapeutics (TRIL) started the year trading around $ 20.13 and today it is at $ 0.00. Follow the real-time price chart, the historical price of Trillium Therapeutics (TRIL) and international markets.

When does Trillium Therapeutics (TRIL) pay dividends?

Trillium Therapeutics (TRIL) did not distribute dividends in the last year.

Is Trillium Therapeutics (TRIL) worth it?

Currently, Trillium Therapeutics (TRIL) is priced at $ 0.00, with a P/E of 31.67%, representing a deviation of 0% from its historical average P/E. In the last year, the stock showed a variation of 0 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 0.00%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Trillium Therapeutics (TRIL) stock?

Investing in stocks of Trillium Therapeutics (TRIL) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Trillium Therapeutics (TRIL) yield today?

The yield of Trillium Therapeutics (TRIL) was 0.00% in the last month, 0.00% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Trillium Therapeutics (TRIL) today, the total investment would be $ 0.00, based on the current price of $ 0.00.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 0.00
In 5 years: $ 0.00
In 10 years: $ 0.00

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

TRIL

Trillium Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TRIL

review the fundamentals of Trillium Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Trillium Therapeutics

Trillium Therapeutics Inc.

United States

22 years

2009

33

PROFIT X PRICE TRIL

Financial Results TRIL

TRIL cash flow

Asset, Revenue and Profit Growth - TRIL

TRIL balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions